ArticleDiscover oncology2025
Application of bioinformatics analysis to construct the prognostic model and immune-related gene characteristics of low-grade glioma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLow-grade gliomas (LGG) are slow-growing brain tumors with limited treatment options, making prognosis challenging. Recent advancements in molecular profiling offer potential for better understanding of genetic and immune factors involved in LGG progression, guiding more effective treatments and improving patient outcomes.
objectivesIn this study, the risk of low-grade gliomas (LGG) was analyzed by gene expression profile to provide a reference for clinical treatment and prognosis observation.
methodsWe employed RNA sequencing information from the International Cancer Genome Consortium (ICGC-US), the Gene Expression Omnibus (GEO), and the Cancer Genome Atlas (TCGA). Analysis Portal and Immunology Database provided information on genes relevant to immunity. To find differential expression of prognostic genes and create signatures, multivariate Cox, univariate, and Lasso regression were utilized. Its capability was assessed using the calibration curve and the receiver operating characteristic. The relationship between the score of risk and the quantity of tumor-invasive immune cells was evaluated using TIMER and CIBERSORTx. The expression of HPSE2 in brain glioma cells was verified by Real-time quantitative polymerase chain reaction (RT-qPCR). The growth and metastatic ability of glioma cells after down-regulation of HPSE2 was detected by biological function assay.
resultsWe identified 37 differential genes associated with LGG prognosis. Thirteen prognostic genes were determined to be risk factors. Prognostic characteristics showed comparable accuracy for overall survival at three and five years in both external (ICGC-US) and internal (TCGA) verification lines. The scores of StromalScore, ImmuneScore, and ESTIMATEScore in the high-risk group were higher than those in the low-risk group. Macrophages M0, memory resting of T cells CD4, memory activated of T cells CD4, B cells naive, the memory of B cells, the level of Macrophages M1 is higher than the group of low-risk. In contrast, T cell CD8, T cells regulatory (Tregs), Monocytes, Mast cells activated levels are lower than the group of low-risk. HPSE 2 was highly expressed in glioma by qRT-PCR, and the growth and metastasis of glioma cells were inhibited by means of HPSE 2 downregulation.
conclusionsOur research constructs a novel prognostic characteristic for LGG that assesses prognosis and is connected to immune infiltration. Downregulation of HPSE 2 inhibited the metastasis and growth of glioma cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.